Friday, July 14, 2017 8:25:23 AM
July 14, 2017 7:31 AM EDT
BTIG initiates coverage on Eiger BioPharma (NASDAQ: EIGR) with a Buy rating and a price target of $32.00.Analyst Robert Hazlett
_________________________________________________________
Consensus Ratings for Eiger BioPharmaceuticals (NASDAQ:EIGR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 5 Buy Ratings
Consensus Rating: Buy (Score: 3.00)
Consensus Price Target: $32.75 (339.60% upside)
_________________________________________________________
https://www.marketbeat.com/stocks/NASDAQ/EIGR/
EIGR
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM